Nasdaq GlobeNewswire

Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer

Del
  • Company strengthens management team with biopharmaceutical veteran bringing extensive commercial experience in life-threatening rare diseases
  • Tim Miller, Ph.D. continues as president and assumes chief scientific officer role

NEW YORK and CLEVELAND, April 02, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of Carsten Thiel, Ph.D., as Chief Executive Officer.  Timothy J. Miller, Ph.D., will remain President and assume the position of Chief Scientific Officer in charge of the company's expanding clinical and preclinical research programs. Dr. Thiel most recently served as the Executive Vice President and Chief Commercial Officer of Alexion Pharmaceuticals, Inc. where he led global commercial operations bringing innovative and life-transformative therapies for rare diseases to patients.

"The past year has been an extraordinary time in the history of Abeona, including significant progress in our clinical development programs and establishment of our new manufacturing facility in Cleveland," said Steven Rouhandeh, Executive Chairman of Abeona.  "As CEO, Carsten Thiel brings a unique combination of extensive experience in research and global rare disease commercialization to Abeona. In his recent positions, he successfully created value by building cohesive talented teams, driving the commercial success of multiple products globally and fostering entrepreneurial culture; all key aspects that will be critical to our success in these areas in the years ahead. We are very grateful to Tim Miller for his vision and leadership that have brought us to this pivotal stage in our business growth."

Dr. Thiel brings 25 years of proven global biopharmaceutical industry experience, including rare and orphan diseases, to Abeona.  Prior to leading his most recent position at Alexion, he served as its Senior Vice President, Europe/Middle East/Africa and Asia Pacific where he was responsible for driving Alexion's global commercial operations in these regions, including maximizing the current rare disease portfolio as well as guiding the launch of anticipated new products and indications. 

"I am thrilled to be joining Abeona during a period of major growth and momentum in the company's range of promising development programs," said Dr. Thiel.  "I look forward to bringing my experience in business development, biomedical research and commercialization to the outstanding Abeona team at a time when the company is ideally positioned to rapidly expand these areas."

Prior to joining Alexion, Dr. Thiel served as Vice President, Head of Europe at Amgen. In this role, he led regional operations and was responsible for multiple products in hematology/oncology, nephrology, and bone disorders, and prepared for new product launches in inflammation and cardiology. He also held various other senior leadership positions at Amgen, including General Manager, Germany, and General Manager, CEE, where he led all markets in Eastern Europe and established Amgen's operations in Russia. He also served as Head of the Oncology franchise in Europe during the time of several blockbuster product launches. Prior to Amgen, Dr. Thiel held several sales and marketing leadership roles across Europe at Roche.

"As Abeona expands our innovative science and clinical research programs into new areas, I look forward to working more closely with our research and product development teams to fuel even greater success for developing novel gene and cell therapies," said Dr. Miller. "We welcome Carsten to our team at Abeona, and remain confident that our clinical advancements and strategic decisions have solidly positioned us to plan for many promising opportunities in global product commercialization and business strategy." 

Dr. Thiel earned his doctorate in molecular biology & biochemistry at Max Planck Institute for Biophysical Chemistry in Goettingen, Germany. 

About Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV-NAGLU), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type B (MPS IIIB).  Abeona is also developing ABO-201 (AAV-CLN3) gene therapy for CLN3 disease (juvenile Batten disease), ABO-202 (AAV-CLN1) for treatment of CLN1 disease (infantile to late infantile Batten), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona is developing a proprietary vector platform, AIM(TM), for next generation product candidates.  For more information, visit www.abeonatherapeutics.com.

Investor Contact:
Christine Silverstein
SVP, Finance & Investor Relations
Abeona Therapeutics Inc.
+1 (646) 813-4707
csilverstein@abeonatherapeutics.com 

Media Contact:
Lynn Granito
Berry & Company Public Relations
+1 (212) 253-8881
lgranito@berrypr.com 

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include statements regarding the expected expansion in our business development, biomedical research and commercialization; our belief that Dr. Miller working more closely with our research and product development teams will fuel even greater success for the development of novel gene and cell therapies; and our expectation that we have many promising opportunities in global product commercialization and business strategies.  We have attempted to identify forward looking statements by such terminology as "may," will," "anticipate," "believe," "estimate," "expect," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, risks and uncertainties, including but not limited to, continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to secure licenses for any technology that may be necessary to commercialize our products; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Abeona Therapeutics Inc via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

OTP Bank Selects eGain’s Knowledge Management for Customer Service26.9.2018 12:30Pressemelding

eGain’s AI and knowledge management solution will be deployed at the bank’s contact centres and retail branches with the support of eGain partner Pattern Digital Consulting SUNNYVALE, Calif. and NEWBURY, United Kingdom, Sept. 26, 2018 (GLOBE NEWSWIRE) -- eGain (NASDAQ: EGAN), the leading provider of cloud-based customer engagement solutions today announced that OTP Bank, one of the largest banks serving Central and Eastern Europe, has selected eGain for omnichannel customer service. Pattern Digital Consulting Ltd., an implementation partner for eGain, will work with eGain Quick Value Services™ team to deploy eGain’s award-winning solution for AI-infused knowledge to provide conversational, procedural, and process guidance to agents at the bank’s contact centers and retail branches. The bank tried out eGain’s solution as part of eGain Try+Buy™ consumption model, which is a risk-free production pilot with no obligation to buy and no-charge guidance for success. Happy with the agent exper

Canadian Natural Resources Limited Announces Completion of the Extension Period to Acquire All Issued and Outstanding Shares of Laricina Energy Ltd.26.9.2018 11:00Pressemelding

CALGARY, Alberta, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Canadian Natural Resources Limited (“Canadian Natural" or the "Company") announces that Canadian Natural's offer to acquire all of the issued and outstanding common shares (the “Laricina Shares") of Laricina Energy Ltd. (“Laricina”) for $0.0815 per Laricina Share by way of a take-over bid (the "Offer"), as extended on September 13, 2018 for the mandatory 10-day extension period, expired at 11:59 p.m. (Mountain Daylight Time) on September 24, 2018. Since Canadian Natural's initial take up of 568,724,430 Laricina Shares on September 13, 2018, Computershare Investor Services Inc., the depositary, has reported that as at 11:59 p.m. (Mountain Daylight Time) on September 24, 2018, an additional 3,594,872 Laricina Shares (the "Additional Shares") were validly deposited under the Offer and not withdrawn. Canadian Natural has taken up and accepted for payment all such Additional Shares and payment for such Additional Shares will be made as so

Juniper Systems Unveils New Cedar CP3 Rugged Smartphone26.9.2018 06:36Pressemelding

BIRMINGHAM, United Kingdom, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Juniper Systems Limited today announced the release of its newest Cedar™ device, the Cedar CP3™ Rugged Smartphone. The rugged smartphone arrives two years after its predecessor, the CT5™ Rugged Smartphone, bringing massive upgrades to nearly every specification. The CP3 touts battery life of 14-16 hours operating at full brightness and while running GPS. The CP3 is powered by a Snapdragon 653 octa-core processor, delivering fast load times and top-tier performance for advanced tasks without draining the battery. ‘Rugged doesn’t have to mean bulky and slow’, said Simon Bowe, general manager of Juniper Systems Limited. ‘The CP3 proves that smartphones can be purpose-built for data collection in the world’s toughest environments – and are also handy for surfing online at home’. The Cedar CP3 Rugged Smartphone is available globally and works on any GSM network. The powerful battery delivers a shocking 480-hour standby time and

Tenaris to acquire significant stake in Saudi Steel Pipe Company25.9.2018 22:58Pressemelding

LUXEMBOURG, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE, Buenos Aires and Mexico: TS and MTA Italy: TEN) announced today that it has entered into a definitive agreement to acquire from a private group 47.79% of the shares of Saudi Steel Pipe Company (“SSP”), a welded steel pipes producer listed on the Saudi stock market, for an aggregate price of US$144 million. The transaction is subject to regulatory approvals, including approval by the Capital Market Authority of Saudi Arabia, and other customary conditions and is expected to close in the first quarter of 2019. Tenaris has been serving Saudi Arabia’s oil and gas industry and Saudi Aramco for decades. With this transaction, Tenaris will significantly expand its industrial presence in the Kingdom and the range of products it supplies to Saudi Aramco. Since its first industrial investment in 2010, Tenaris has continuously invested to expand its local operations, supporting the industrialization of the country. SSP’s facilitie

Navigators Announces End of “Go-Shop” Period25.9.2018 22:01Pressemelding

STAMFORD, Conn., Sept. 25, 2018 (GLOBE NEWSWIRE) -- The Navigators Group, Inc. (NASDAQ:NAVG) (“Navigators”) today announced the expiration of the 30-day “go-shop” period provided for under the terms of the previously announced definitive merger agreement (the “Merger Agreement”), pursuant to which Navigators will be acquired by The Hartford Financial Services Group, Inc. Under the terms of the Merger Agreement, Navigators and its representatives were permitted to initiate, solicit and engage in discussions or negotiations with respect to alternative acquisition proposals from third parties until 12:01 a.m. (New York City time) on September 21, 2018 (the “go-shop period”). During the go-shop period, Navigators and its financial advisors, Goldman Sachs & Co. LLC and Moelis & Company LLC, solicited 44 potential acquirers. Despite these efforts, Navigators did not receive any alternative acquisition proposals during the go-shop period. Immediately following the expiration of the go-shop pe

Code Pilot Launches Employer "Radar” Product, Makes Hiring Validated Technical Talent a Reality25.9.2018 21:25Pressemelding

Austin-Based Startup aims to offer hiring partners a meritocratic tool that is free from unconscious bias and puts the emphasis back on hard skills AUSTIN, Texas, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Code Pilot, a new data science platform, launched its “Radar” product today which enables companies to hire software engineers at scale with confidence and intelligence. The Bureau of Labor Statistics highlights that over 41 million people are searching and being recruited into jobs in the US every year. A massive issue in the current hiring landscape is exposed by the findings of Brandon Hall’s research brief that found a staggering 95 percent of employers surveyed admitted to making hiring mistakes by recruiting the wrong people each year. Code Pilot’s Radar aims to solve this issue by validating candidates and eliminating the noise often caused by cognitive bias. The Radar product has two distinct offerings: Test Manager uses advanced automation with a series of proprietary code assessmen

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom